Clinical and Molecular Hepatology (대한간학회지)

The Korean Association for the Study of the Liver (대한간학회)
권호 표지
DOI QR코드

DOI QR Code

Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals

  • Ko, Soon Young (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Choe, Won Hyeok (Department of Internal Medicine, Konkuk University School of Medicine)
  • Received : 2017.10.27
  • Accepted : 2018.01.02
  • Published : 2018.12.25
⟨ Previous Next ⟩

Abstract

The advent of novel, direct-acting antiviral (DAA) regimens for hepatitis C virus (HCV) infection has revolutionized its treatment by producing a sustained virologic response of more than 95% with few side effects and no comorbidities in the general population. Until recently, ideal DAA regimens have not been available to patients with severe renal impairment and end-stage renal disease because there are limited data on the pharmacokinetics, safety, and efficacy of treatment in this unique population. In a hemodialysis context, identifying patients in need of treatment and preventing HCV transmission may also be a matter of concern. Recently published studies suggest that a combination of paritaprevir/ritonavir/ombitasvir and dasabuvir, elbasvir/grazoprevir, or glecaprevir/pibrentasvir successfully treats HCV infection in chronic kidney disease stage 4 or 5 patients with or without hemodialysis.

Keywords

References

  1. Suh DJ, Jeong SH. Current status of hepatitis C virus infection in Korea. Intervirology 2006;49:70-75. https://doi.org/10.1159/000087266
  2. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61(1 Suppl):S45-S57. https://doi.org/10.1016/j.jhep.2014.07.027
  3. Smolders EJ, de Kanter CT, van Hoek B, Arends JE, Drenth JP, Burger DM. Pharmacokinetics, efficacy, and safety of hepatitis c virus drugs in patients with liver and/or renal impairment. Drug Saf 2016;39:589-611. https://doi.org/10.1007/s40264-016-0420-2
  4. Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol 2016;22:76-139. https://doi.org/10.3350/cmh.2016.22.1.76
  5. Jin DC, Yun SR, Lee SW, Han SW, Kim W, Park J. Current characteristics of dialysis therapy in Korea: 2015 registry data focusing on elderly patients. Kidney Res Clin Pract 2016;35:204-211. https://doi.org/10.1016/j.krcp.2016.09.006
  6. Isnard Bagnis C, Cacoub P. Hepatitis C therapy in renal patients: who, how, when? Infect Dis Ther 2016;5:313-327. https://doi.org/10.1007/s40121-016-0116-z
  7. Carvalho-Filho RJ, Feldner AC, Silva AE, Ferraz ML. Management of hepatitis C in patients with chronic kidney disease. World J Gastroenterol 2015;21:408-422. https://doi.org/10.3748/wjg.v21.i2.408
  8. Racanelli V, Rehermann B. Hepatitis C virus infection: when silence is deception. Trends Immunol 2003;24:456-464. https://doi.org/10.1016/S1471-4906(03)00178-9
  9. Thomson EC, Smith JA, Klenerman P. The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals. J Gen Virol 2011;92:2227-2236. https://doi.org/10.1099/vir.0.033910-0
  10. Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int 2016;10:702-726. https://doi.org/10.1007/s12072-016-9717-6
  11. Patel PR, Thompson ND, Kallen AJ, Arduino MJ. Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients. Am J Kidney Dis 2010;56:371-378. https://doi.org/10.1053/j.ajkd.2010.01.025
  12. Hardy NM, Sandroni S, Danielson S, Wilson WJ. Antibody to hepatitis C virus increases with time on hemodialysis. Clin Nephrol 1992;38:44-48.
  13. Niu MT, Coleman PJ, Alter MJ. Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members. Am J Kidney Dis 1993;22:568-573. https://doi.org/10.1016/S0272-6386(12)80930-9
  14. Thompson ND, Perz JF, Moorman AC, Holmberg SD. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008. Ann Intern Med 2009;150:33-39. https://doi.org/10.7326/0003-4819-150-1-200901060-00007
  15. Thompson ND, Novak RT, Datta D, Cotter S, Arduino MJ, Patel PR, et al. Hepatitis C virus transmission in hemodialysis units: importance of infection control practices and aseptic technique. Infect Control Hosp Epidemiol 2009;30:900-903. https://doi.org/10.1086/605472
  16. Girou E, Chevaliez S, Challine D, Thiessart M, Morice Y, Lesprit P, et al. Determinant roles of environmental contamination and noncompliance with standard precautions in the risk of hepatitis C virus transmission in a hemodialysis unit. Clin Infect Dis 2008;47:627-633. https://doi.org/10.1086/590564
  17. Bialek SR, Terrault NA. The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis 2006;10:697-715. https://doi.org/10.1016/j.cld.2006.08.003
  18. Prati D. Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J Hepatol 2006;45:607-616. https://doi.org/10.1016/j.jhep.2006.07.003
  19. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001;50:1-43.
  20. Webster DP, Wojcikiewicz T, Keller M, Castelnovo D, Mistry H, Gilleece Y, et al. Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and ribavirin. Int J STD AIDS 2013;24:179-183. https://doi.org/10.1177/0956462412472317
  21. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet 2015;385:1124-1135. https://doi.org/10.1016/S0140-6736(14)62401-6
  22. Lemos LB, Perez RM, Matos CA, Silva IS, Silva AE, Ferraz ML. Clinical and laboratory characteristics of acute hepatitis C in patients with end-stage renal disease on hemodialysis. J Clin Gastroenterol 2008;42:208-211. https://doi.org/10.1097/MCG.0b013e31802dc57f
  23. Okuda K, Hayashi H, Yokozeki K, Kobayashi S, Kashima T, Irie Y. Acute hepatitis C among renal failure patients on chronic haemodialysis. J Gastroenterol Hepatol 1998;13:62-67. https://doi.org/10.1111/j.1440-1746.1998.tb00547.x
  24. Brown DL, Emerson DS. A prospective evaluation of fetal pericardial fluid in 506 second-trimester low-risk pregnancies. Obstet Gynecol 1998;91:641; author reply 642. https://doi.org/10.1016/S0029-7844(98)00058-1
  25. Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: metaanalysis of observational studies. J Viral Hepat 2007;14:697-703.
  26. Scott DR, Wong JK, Spicer TS, Dent H, Mensah FK, McDonald S, et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation 2010;90:1165-1171. https://doi.org/10.1097/TP.0b013e3181f92548
  27. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008;(109):S1-99.
  28. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982. https://doi.org/10.1056/NEJMoa020047
  29. Engel M, Malta FM, Gomes MM, Mello IM, Pinho JR, Ono-Nita SK, et al. Acute hepatitis C virus infection assessment among chronic hemodialysis patients in the Southwest Parana State, Brazil. BMC Public Health 2007;7:50. https://doi.org/10.1186/1471-2458-7-50
  30. Liu CH, Liang CC, Liu CJ, Lin JW, Chen SI, Hung PH, et al. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C. Clin Infect Dis 2010;51:541-549. https://doi.org/10.1086/655682
  31. Bhamidimarri KR, Martin P. Finally, safe and effective treatment options for hepatitis C in hemodialysis patients. J Hepatol 2016;65:7-10. https://doi.org/10.1016/j.jhep.2016.04.003
  32. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34-44. https://doi.org/10.1056/NEJMoa1208953
  33. Hundemer GL, Sise ME, Wisocky J, Ufere N, Friedman LS, Corey KE, et al. Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infect Dis (Lond) 2015;47:924-929. https://doi.org/10.3109/23744235.2015.1078908
  34. Korean Association for the Study of the Liver. 2017 KASL clinical prractice guidelines management of hepatitis C: Treatment of chronic hepatitis C. Seoul: Jin Publishing Co., 2017:1-152.
  35. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 2017;66:153-194. https://doi.org/10.1016/j.jhep.2016.09.001
  36. AASLD. Hepatitis C guidance: Recommendations for testing, managing, and treating hepatitis C virus. IDSA web site, . Accessed 11 Oct 2017.
  37. Saxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int 2016;36:807-816. https://doi.org/10.1111/liv.13102
  38. Bhamidimarri KR, Czul F, Peyton A, Levy C, Hernandez M, Jeffers L, et al. Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease. J Hepatol 2015;63:763-765. https://doi.org/10.1016/j.jhep.2015.06.004
  39. Desnoyer A, Pospai D, Le MP, Gervais A, Heurgue-Berlot A, Laradi A, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvirbased regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol 2016;65:40-47. https://doi.org/10.1016/j.jhep.2016.02.044
  40. Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 2016;150:1590-1598. https://doi.org/10.1053/j.gastro.2016.02.078
  41. Suda G, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kobayashi T, et al. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol 2016;51:733-740. https://doi.org/10.1007/s00535-016-1162-8
  42. Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, et al. Grazoprevir plus elbasvir in treatment-naive and treatmentexperienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015;386:1537-1545. https://doi.org/10.1016/S0140-6736(15)00349-9
  43. Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Brau N, Brown A, et al. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. N Engl J Med 2017;377:1448-1455. https://doi.org/10.1056/NEJMoa1704053